U.S. Tariff Revenue in April Soars 130% Year-on-Year to $16 Billion
According to data from the U.S. Treasury Department, tariff revenue in April reached $16 billion, a surge of $9 billion compared to the same period last year, marking an increase of 130%. Based on data compiled by Bloomberg, this sets a record for the highest monthly tariff revenue in at least a decade. The surge in tariff revenue helps curb the further expansion of the U.S. budget deficit. However, U.S. President Trump is seeking to reach trade agreements with specific countries, which may lead to a reduction in future tariff revenue. In the first seven months of this fiscal year, the U.S. federal government recorded a deficit of $1.05 trillion, which, after adjusting for calendar year differences, expanded by 13% compared to the same period last year. Treasury officials stated that excluding the deferred tax factors that boosted fiscal year 2024 revenue, the actual deficit increase for fiscal year 2025 is 4%. Besides tariffs, another revenue category that achieved growth this fiscal year is excise taxes, which have increased by $10 billion over the past seven months. Treasury officials indicated that this is mainly due to the newly imposed stock buyback tax.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

